IDO Targeting in Sarcoma: Biological and Clinical Implications

Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy. We recently demonstrated an increase in Kynurenine Pathway (KP) activity in the plasma of sarcoma patients treated with pembrolizumab. While the KP has already been described to favor immune escape...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Nafia, Imane, Toulmonde, Maud, Bortolotto, Doriane, Chaibi, Assia, Bodet, Dominique, Rey, Christophe, Velasco, Valerie, Larmonier, Claire B., Cerf, Loïc, Adam, Julien, Le Loarer, François, Savina, Ariel, Bessede, Alban, Italiano, Antoine
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066301/
https://ncbi.nlm.nih.gov/pubmed/32194552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00274
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars